A detailed history of Northern Trust Corp transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 100,396 shares of AVTE stock, worth $261,029. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100,396
Previous 95,737 4.87%
Holding current value
$261,029
Previous $158,000 32.28%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.61 - $2.09 $7,500 - $9,737
4,659 Added 4.87%
100,396 $209,000
Q2 2024

Aug 14, 2024

SELL
$1.41 - $30.75 $3,979 - $86,776
-2,822 Reduced 2.86%
95,737 $158,000
Q1 2024

May 14, 2024

SELL
$17.68 - $29.57 $17,114 - $28,623
-968 Reduced 0.97%
98,559 $2.91 Million
Q4 2023

Feb 13, 2024

SELL
$9.58 - $24.25 $104,575 - $264,713
-10,916 Reduced 9.88%
99,527 $2.25 Million
Q3 2023

Nov 13, 2023

BUY
$12.9 - $18.88 $289,553 - $423,780
22,446 Added 25.51%
110,443 $1.5 Million
Q2 2023

Aug 11, 2023

BUY
$15.63 - $22.01 $165,021 - $232,381
10,558 Added 13.63%
87,997 $1.51 Million
Q1 2023

May 15, 2023

SELL
$19.17 - $27.7 $14,569 - $21,052
-760 Reduced 0.97%
77,439 $1.56 Million
Q4 2022

Feb 13, 2023

BUY
$15.92 - $30.52 $53,666 - $102,882
3,371 Added 4.5%
78,199 $2.29 Million
Q3 2022

Nov 14, 2022

SELL
$14.77 - $25.79 $19,378 - $33,836
-1,312 Reduced 1.72%
74,828 $1.24 Million
Q2 2022

Aug 12, 2022

SELL
$10.8 - $16.91 $305,748 - $478,722
-28,310 Reduced 27.1%
76,140 $1.19 Million
Q1 2022

May 13, 2022

BUY
$8.25 - $18.33 $142,568 - $316,760
17,281 Added 19.82%
104,450 $1.92 Million
Q4 2021

Feb 08, 2022

SELL
$9.14 - $21.54 $9,469 - $22,315
-1,036 Reduced 1.17%
87,169 $1.03 Million
Q3 2021

Nov 15, 2021

BUY
$11.76 - $22.49 $1.04 Million - $1.98 Million
88,205 New
88,205 $1.85 Million

Others Institutions Holding AVTE

About Aerovate Therapeutics, Inc.


  • Ticker AVTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,448,100
  • Market Cap $63.6M
  • Description
  • Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...
More about AVTE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.